Flagship and GSK Initiate Feasibility Agreements with ProFound and Quotient

Flagship Pioneering, known for its pioneering scientific innovations, has announced that ProFound Therapeutics and Quotient Therapeutics have entered separate feasibility agreements with GSK. These agreements aim to discover and validate novel therapeutic targets for respiratory and liver diseases, marking the first company-focused agreements under the collaborative framework established between Flagship and GSK. "Flagship Pioneering and GSK have a shared mission to accelerate the development of breakthrough medicines for patients with the greatest unmet needs by combining innovative new technologies with deep drug development expertise," said Paul Biondi, Managing Partner, Flagship Pioneering. He added, "These agreements bring together two pioneering approaches to advance innovative treatments for respiratory and liver diseases, and to identify novel and differentiated targets that may alter the course of disease."

ProFound Therapeutics plans to utilize its ProFoundry™ Platform, which incorporates advanced protein detection technologies and computational tools, to explore the expanded human proteome. This platform will help identify potential protein drugs and targets linked to Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF). Through two separate agreements, ProFound will work to characterize these novel proteins and assess their therapeutic relevance for these conditions.

On the other hand, Quotient Therapeutics will employ its innovative Somatic Genomics platform to investigate the natural genetic diversity in patients, aiming to uncover new therapeutic strategies for various diseases. Quotient will engage in three agreements to identify disease-causal drug targets that could lead to breakthrough treatments for COPD, IPF, and Metabolic Dysfunction-Associated Steatohepatitis (MASH). If GSK opts to further collaborate, ProFound and Quotient will advance their programs through critical preclinical activities, after which GSK will hold the exclusive option to push these programs into clinical trials.